On March 26, the US Food and Drug Administration (FDA) approved cabozantinib for the treatment of adult and pediatric patients aged 12 years or older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors and well-differentiated extra-pancreatic neuroendocrine tumors.

For more information, read the FDA announcement or the Exelixis press release.

Posted on 3/26/25